PURPOSE: Small cell lung cancer is one of cancers with high mortality rate. Etoposide/cisplatin or recently irinotecan/cisplatin have shown an excellent anti-tumor effect against SCLC. However, short response duration and rare long-term survival have been characterized although it has high response to combination chemotherapy. CKD-602 (Belotecan) is a new camptothecin derivative anti-tumor agent that belong to the topoisomerase inhibitors developed by Chong Kun Dang pharmaceutical company in Korea. Preclinical studies suggest that it may have greater anti-tumor activity and lower toxicity than other camptothecin anticancer agents.
METHODS: Patients with limited stage SCLC which progressed after it had responded to prior chemotherapy or extensive stage SCLC, were included. Patients with no measurable lesions, brain metastasis, prior chemotherapy with topoisomerase inhibitor such as topotecan and irinotecan were excluded. The dose and schedule of CKD-602 at 1st cycle was 0.5mg/m2/day for 30 min every 3 weeks and then the dose was modified according to the toxicity.
RESULTS: From March 2005 to February 2006, the total numbers of registered patients were 37. Among them, 37 patients were evaluable for the toxicity, 19 for the response. Mean cycle was 3.4 (range, 1 - 9). The response rate was 66.6% for 1st line chemotherapy, and 28.6% for 2nd line chemotherapy. 62.1% and 29.7% of patients experienced grade 3-4 neutropenia and thrombocytopenia, respectively, without a treatment-related death.
CONCLUSION: CKD-602 (Belotecan), a new camptothecin analogue, showed activity and acceptable toxicities as a single agent in patients with SCLC.
CLINICAL IMPLICATIONS: CKD-602 can be used as treatment with promising response rates in SCLC.
DISCLOSURE: Jin Woo Kim, None.